Document is current
Any future updates will be listed below
-
Authors
Peters, Finn https://orcid.org/0000-0002-3062-9825
Salihoglu, Hazal
Pratsch, Katrin
Herzog, Etienne https://orcid.org/0000-0002-0058-6959
Pigoni, Martina
Sgobio, Carmelo https://orcid.org/0000-0002-6282-369X
Lichtenthaler, Stefan F https://orcid.org/0000-0003-2211-2575
Neumann, Ulf https://orcid.org/0000-0001-6680-9177
Herms, Jochen https://orcid.org/0000-0002-6201-1042
-
Funding
Funding for this research was provided by:
Munich Cluster for Systems Neurology (EXC1010)
ITN Extrabrain (606950)
ITN SynDegen (721802)
Centers of Excellence in Neurodegeneration
- License Information
-
More Information
Article History
Received: 29 April 2019
Revised: 29 September 2019
Accepted: 8 October 2019
First Online: 7 November 2019
Conflict of interest
: F.P. is full‐time employee at Evotec (Hamburg, Germany). H.S. is full‐time employee at Betapharm (Augsburg, Germany), and U.N. is full‐time employee at Novartis Pharma AG (Basel, Switzerland). All other authors declare that they have no conflict of interest.
